Pirarubicin

Pirarubicin is an anthracycline antibiotics, acts as a topoisomerase II inhibitor, and is a widely used for treatment of various cancers, in particular, solid tumors.

Product Specifications

CAS Number

[72496-41-4]

Product Name Alternative

THP

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Antibiotic; Autophagy; Bacterial; Topoisomerase

Type

Reference compound

Related Pathways

Anti-infection; Autophagy; Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/Pirarubicin.html

Purity

99.61

Solubility

DMSO : 10 mg/mL (ultrasonic; warming; heat to 80°C)

Smiles

O=C1C2=C(C=CC=C2OC)C(C3=C(O)C4=C([C@@H](O[C@@]5([H])C[C@H](N)[C@H](O[C@@]6([H])OCCCC6)[C@H](C)O5)C[C@@](C(CO)=O)(O)C4)C(O)=C31)=O

Molecular Formula

C32H37NO12

Molecular Weight

627.64

Precautions

H302, H315, H319, H335

References & Citations

[1]Takigawa N, et al. Cytotoxic effect of topoisomerase II inhibitors against adriamycin- and etoposide-resistant small cell lung cancer sublines. Gan To Kagaku Ryoho. 1993 May;20 (7) :929-35.|[2]Nagai K, et al. Relationships between the in vitro cytotoxicity and transport characteristics of pirarubicin and doxorubicin in M5076 ovarian sarcoma cells, and comparison with those in Ehrlich ascites carcinoma cells. Cancer Chemother Pharmacol. 2002 Mar;49 (3) :244-50. Epub 2002 Jan 8.|[3]Li K, et al. Pirarubicin induces an autophagic cytoprotective response through suppression of the mammalian target of rapamycin signaling pathway in human bladder cancer cells. Biochem Biophys Res Commun. 2015 May 1;460 (2) :380-5.|[4]Wang YD, et al. Cardioprotective effects of rutin in rats exposed to pirarubicin toxicity. J Asian Nat Prod Res. 2017 Oct 27:1-13.